Biography of Thomas C. Abshire, MD
Professor of Pediatrics
Hemophilia of Georgia, Inc., Director's Chair in Hemostasis
Aflac Cancer Center and Blood Disorders Service
Children's Healthcare of Atlanta
Emory University School of Medicine
Atlanta, Georgia
Thomas Abshire, MD, holds the Hemophilia of Georgia, Inc., director's chair in hemostasis and is a professor of pediatrics and director of the comprehensive hemophilia program at Emory University and Children's Healthcare of Atlanta. He also is the medical director, MCHB Hemophilia Region, IVS. Dr. Abshire is a distinguished graduate of the United States Air Force Academy. He attended medical school at Tulane University, fulfilled his pediatric residency training at David Grant USAF Medical Center and completed pediatric hematology/oncology fellowship training at the University of Colorado Health Science Center. Prior to joining the faculty at Emory University, Dr. Abshire completed a career in the United States Air Force with an emphasis as a clinician-educator, where he was the recipient of several medical student and housestaff teaching awards. He also was the PI for SIMAL 7, a relapsed ALL clinical trial within the Pediatric Oncology Group (POG).
During his 20 years as a practicing pediatric hematologist/oncologist, Dr. Abshire has maintained a steady involvement with clinical trials and new product development in hemostasis and thrombosis including laboratory evaluation of mild bleeding disorders and therapeutic intervention in hemophilia, von Willebrand disease, and thrombosis. He has published 50 peer-reviewed manuscripts, review articles or editorials, and is a frequently invited speaker at national and international meetings. Dr. Abshire holds memberships in several academic societies including the Society for Pediatric Research (SPR), the American Society of Hematology (ASH), the International Society of Thrombosis and Hemostasis (ISTH), and the American Society of Pediatric Hematology/Oncology (ASPHO). He also serves on the steering committee of the International Immune Tolerance Study.